Skip to main content

Table 2 Comparison of SVR rates between two PEG-IFN groups according to categorized variables

From: Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population

Genotype 1 PEG-IFN alfa-2a PEG-IFN alfa-2b P*
(n=416) (n=254) (n=162)  
SVR, n (%) 158 (62.2) 104 (64.2) 0.76
 Age, n (%)    
 ≤50 years (n=212) 88/133 (66.2) 61//79 (77.2) 0.12
>50 years (n=204) 70/121 (57.9) 43/83 (51.8) 0.47
HCV RNA (IU/mL), n (%)    
 ≤7×105(n=149) 76/117 (65.0) 46/67 (68.7) 0.63
 >7×105(n=232) 82/137 (59.9) 58/95 (61.1) 0.89
Liver fibrosis, n (%)    
 F 0–2 (n=80) 48/62 (77.4) 11/18 (61.1) 0.22
 F 3–4 (n=49) 18/43 (41.9) 4/6 (66.7) 0.39
Genotype 2/3 PEG-IFN alfa-2a PEG-IFN alfa-2b 0.29
(n=235) (n=141) (n=94)  
SVR, n (%) 112 (79.4) 75 (79.8) 1.00
 Age, n (%)    
 ≤50 years (n=125) 71/80 (88.8) 38/45 (84.4) 0.58
>50 years(n=110) 41/61 (67.2) 37/49 (75.5) 0.40
 HCV RNA (IU/mL), n (%)    
 ≤7×105 (n=137) 63/81(77.8) 49/56 (87.5) 0.18
 >7×105 (n=98) 49/60 (81.7) 26/38 (68.4) 0.15
Liver fibrosis, n (%)    
 F 0–2 (n=59) 42/51 (82.4) 7/8 (87.5) 1.00
 F 3–4 (n=15) 7/10 (70.0) 3/5 (60.0) 1.00
  1. Abbreviation: HCV, hepatitis C virus; PEG-IFN, peginterferon; SVR, sustained virologic response.
  2. †, ‡ Data were available in 129 and 74 patients, respectively. If the number of patients was smaller than 5, Fisher’s exact test was used.